Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTXFI1K)

DTT Name Hyaluronidase (HYAL)
Gene Name HYAL
DTT Type
Successful target
 [1]
BioChemical Class
Glycosylase
UniProt ID
NOUNIPROTAC
TTD ID
T93662

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Asenapine DMSQZE2 Schizophrenia 6A20 Approved [1]
Hyqvia DM0RXF5 Immunodeficiency 4A00-4A85 Approved [2]
------------------------------------------------------------------------------------
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
PEGPH20 DM26YJ1 Non-small-cell lung cancer 2C25.Y Phase 2 [3]
PEGylated hyaluronidase (human recombinant) DM1D6BT Pancreatic cancer 2C10 Phase 1/2 [4]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296.